{"schema_version":"secwatch.filing_event.v1","accession":"0001658247-25-000018","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.063940+00:00","generated_at":"2026-05-16T23:45:43.341006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Crinetics Q3 net loss $130.1M; PALSONIFY launched for acromegaly after FDA approval","bullets":["PALSONIFY (paltusotine) approved by FDA Sept 25 for first-line acromegaly; ~95% of top-priority HCP targets called, ~50% of filled prescriptions reimbursed.","Q3 2025 net loss $130.1M vs $76.8M YoY; R&D $90.5M (+46%), SG&A $52.3M (+102%) driven by launch and pipeline.","Cash, equivalents and investments $1.1B; cash burn guidance $340-370M for 2025; runway into 2029.","Phase 3 CAREFNDR (carcinoid syndrome) and Phase 3 CALM-CAH (CAH) expected to start Q4 2025; Phase 1/2 CRN09682 also Q4.","TSHR antagonist program shifted to alternative candidate; SST3 IND postponed after preclinical data."],"urls":{"canonical":"https://secwatch.observer/filing/0001658247-25-000018","json":"https://secwatch.observer/filing/0001658247-25-000018.json","markdown":"https://secwatch.observer/filing/0001658247-25-000018.md","text":"https://secwatch.observer/filing/0001658247-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000165824725000018/0001658247-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000165824725000018/crnx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:45:43.341006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}